Epigenetic regulation of T cell exhaustion in cancer
- 27 October 2025
- journal article
- review article
- Published by Springer Nature in Nature Reviews Cancer
- Vol. 26 (1) , 46-61
Abstract
Current T cell-based immunotherapy strategies, including immune checkpoint blockade (ICB) and chimeric antigen receptor (CAR) T cells, have revolutionized cancer care. However, many patients with cancer who are treated with these approaches fail to respond or do not achieve durable protection against disease relapse, highlighting the need for further optimization of such strategies. The advent of cancer immunotherapy has ushered in an era of research centred on immune oncology with a specific focus on defining T cell-intrinsic mechanisms that delineate therapeutic responders and non-responders. Among the major barriers limiting immunotherapy efficacy, T cell exhaustion — which is characterized by repression of the effector functions and proliferative potential of T cells — has emerged as a common mechanism among various cancers. Here, we review transcriptional and epigenetic mechanisms that control T cell exhaustion. We discuss how T cell subset-specific gene regulatory programmes limit immunotherapy success and theorize on the development of next-generation strategies for increasing the clinical breadth, efficacy and durability of T cell immunotherapy.Keywords
This publication has 157 references indexed in Scilit:
- Lineage tracing reveals clonal progenitors and long-term persistence of tumor-specific T cells during immune checkpoint blockadeCancer Cell, 2023
- The primordial differentiation of tumor-specific memory CD8+ T cells as bona fide responders to PD-1/PD-L1 blockade in draining lymph nodesCell, 2022
- Genome-wide CRISPR screens of T cell exhaustion identify chromatin remodeling factors that limit T cell persistenceCancer Cell, 2022
- Tumor-associated high endothelial venules mediate lymphocyte entry into tumors and predict response to PD-1 plus CTLA-4 combination immunotherapyCancer Cell, 2022
- The PD-1/PD-L1-Checkpoint Restrains T cell Immunity in Tumor-Draining Lymph NodesCancer Cell, 2020
- Dysfunctional CD8 T Cells Form a Proliferative, Dynamically Regulated Compartment within Human MelanomaCell, 2018
- Defining T Cell States Associated with Response to Checkpoint Immunotherapy in MelanomaCell, 2018
- De Novo Epigenetic Programs Inhibit PD-1 Blockade-Mediated T Cell RejuvenationCell, 2017
- The Immunoreceptor TIGIT Regulates Antitumor and Antiviral CD8 + T Cell Effector FunctionCancer Cell, 2014
- IL-7 + IL-15 are superior to IL-2 for the ex vivo expansion of 4T1 mammary carcinoma-specific T cells with greater efficacy against tumors in vivoBreast Cancer Research and Treatment, 2009